– USA, CA – Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced the appointment of Catherine Friedman, a financial industry expert with nearly 40 years of financial industry experience, to its board of directors.
“Cathy is a remarkable financial leader who has an extensive wealth of knowledge and experience from a deep career in the healthcare industry,” said CEO, Jeff Hatfield. “Cathy’s combined history in investment banking, along with the board roles she has held within the biotech industry over the last 15 years, brings a unique and valuable perspective to our growing company. We are thrilled to welcome her to our team, particularly as we advance our lead programs toward clinical development.”
About Cathy Friedman
Cathy Friedman is an independent financial consultant who has been serving public and private companies in the life sciences industry since 2006. Previously, Ms. Friedman held numerous executive positions during a 23-year investment banking career with Morgan Stanley, including managing director, and head of West Coast Healthcare, and co-head of the Biotechnology Practice. Ms. Friedman is the chair of the board of directors for GRAIL, Inc. and also serves as a member of the boards of Altaba Inc., Radius Health, and Lyell Immunopharma, Inc. She is a trustee of The Darden School Foundation at the University of Virginia.
“Vividion has a one-of-a-kind opportunity to address an untapped area of drug development with a pipeline of programs aimed at treating a wide range of underserved cancer and immunology indications,” said Ms. Friedman. “I am excited to partner with this distinguished team and to support their continued evolution as they work to bring their programs into the clinic and, ultimately, deliver them to patients.”
Ms. Friedman holds a B.A. in economics from Harvard University and an MBA from The University of Virginia’s Darden School of Business.
About Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small-molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology.
For more information: https://vividion.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
